1. 3010 Phase, randomized trial (CheckMate 057) of nivolumab (NIVO) vs docetaxel (DOC) in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): Subgroup analyses and patient reported outcomes (PROs). (September 2015) Authors: Horn, L.; Brahmer, J.; Reck, M.; Borghaei, H.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; Barlesi, F.; Kohlhäufl, M.J.; Burgio, M.A.; Fayette, J.; Gettinger, S.N.; Harbison, C.T.; Li, A.; Finckenstein, F.G.; Paz-Ares, L. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S599 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses. (September 2015) Authors: Gettinger, S.N.; Hellmann, M.D.; Shepherd, F.A.; Antonia, S.J.; Brahmer, J.; Chow, L.Q.; Goldman, J.; Juergens, R.; Borghaei, H.; Ready, N.E.; Gerber, D.E.; Nathan, F.; Shen, Y.; Harbison, C.T.; Rizvi, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S632 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 3097 Safety and efficacy of first-line nivolumab (NIVO) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). (September 2015) Authors: Hellmann, M.D.; Rizvi, N.; Gettinger, S.N.; Goldman, J.; Chow, L.Q.; Juergens, R.; Borghaei, H.; Brahmer, J.; Shen, Y.; Harbison, C.T.; Nathan, F.; Ready, N.E.; Antonia, S.J. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S632 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. (September 2015) Authors: Giaccone, G.; Camidge, D.R.; Liu, S.V.; Powderly, J.; Hodi, F.S.; Gettinger, S.N.; Heist, R.S.; Liu, B.; Wallin, J.; Funke, R.; Waterkamp, D.; Ready, N.E. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 7LBA Safety, activity, and response durability assessment of single agent rovalpituzumab tesirine, a delta-like protein 3 (DLL3)-targeted antibody drug conjugate (ADC), in small cell lung cancer (SCLC). (September 2015) Authors: Pietanza, M.C.; Spigel, D.; Bauer, T.M.; Ready, N.E.; Glisson, B.S.; Morgensztern, D.; Robert, F.; Salgia, R.; Kochendorfer, M.; Patel, M.; Strickland, D.K.; Govindan, R.; Burris, H.A.; Rudin, C.M.; Dylla, S. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S712 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗